Deborah Knobelman's Insider Trades & SAST Disclosures
Deborah Knobelman's most recent trade in Kronos Bio Inc was a trade of 246,390 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 3, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Deborah Knobelman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 246,390 | 246,390 | - | - | Employee Stock Option (Right to Buy) | |
| Kronos Bio Inc | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 164,260 | 164,260 | - | 0 | Common Stock | |
| Senti Biosciences Inc. | Knobelman Deborah | Chief Financial Officer, Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 152,000 | 152,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer, Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 101,000 | 131,000 | - | 0 | Common Stock | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 30,000 | 30,000 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges